Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Home Depot reported for 2022

2/21/23 HD

Polyus will reconsider the terms of the feasibility study project at Sukhoy Log deposit

2/21/23 PLZL

SUAL Partners demands justification of Rusal's purchase of RusHydro shares

2/21/23 RUAL

Polyus produced 6% less gold in 2022

2/21/23 PLZL

Board of Directors of TCS Group left two Cypriot nationals

2/21/23 T

Rosseti Urals buys Fortum's assets in the Chelyabinsk region

2/20/23 MRKU

Tattelecom reported for 2022 according to RAS

2/20/23 TTLK

Tatneft may create representative offices in Turkey

2/20/23 TATN

Joint venture of Sollers and Isuzu filed for liquidation

2/20/23 SVAV

MMK plant in Turkey was not damaged by the earthquake and resumes work

2/20/23 MAGN